Analysts Set Pediatrix Medical Group, Inc. (NYSE:MD) Price Target at $21.00

Pediatrix Medical Group, Inc. (NYSE:MD) has earned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $21.00.

MD has been the subject of a number of recent analyst reports. Zacks Research raised Pediatrix Medical Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 21st. Weiss Ratings restated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Monday, December 29th. UBS Group increased their price objective on shares of Pediatrix Medical Group from $16.50 to $23.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. Wall Street Zen raised shares of Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 4th. Finally, Truist Financial upped their target price on shares of Pediatrix Medical Group from $17.00 to $24.00 and gave the stock a “hold” rating in a research report on Monday, November 10th.

Insider Buying and Selling at Pediatrix Medical Group

In other news, Director Laura A. Linynsky sold 10,000 shares of Pediatrix Medical Group stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $21.65, for a total value of $216,500.00. Following the sale, the director directly owned 32,232 shares of the company’s stock, valued at approximately $697,822.80. The trade was a 23.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Mark S. Ordan sold 23,000 shares of the business’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $22.41, for a total value of $515,430.00. Following the completion of the sale, the chief executive officer owned 302,805 shares in the company, valued at $6,785,860.05. This represents a 7.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 43,478 shares of company stock valued at $972,924 in the last 90 days. Insiders own 0.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Marshall & Sullivan Inc. WA bought a new stake in Pediatrix Medical Group in the second quarter worth $41,000. Canada Pension Plan Investment Board bought a new stake in shares of Pediatrix Medical Group in the 2nd quarter worth about $83,000. Quantbot Technologies LP bought a new stake in shares of Pediatrix Medical Group in the 2nd quarter worth about $99,000. Smartleaf Asset Management LLC raised its position in shares of Pediatrix Medical Group by 10.6% during the 3rd quarter. Smartleaf Asset Management LLC now owns 6,250 shares of the company’s stock valued at $101,000 after buying an additional 601 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Pediatrix Medical Group by 219.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,685 shares of the company’s stock valued at $110,000 after acquiring an additional 5,278 shares during the last quarter. 97.71% of the stock is owned by hedge funds and other institutional investors.

Pediatrix Medical Group Stock Performance

MD opened at $22.69 on Friday. The firm has a market cap of $1.95 billion, a P/E ratio of 11.94 and a beta of 0.73. Pediatrix Medical Group has a 1-year low of $11.84 and a 1-year high of $24.99. The company has a 50 day simple moving average of $22.48 and a two-hundred day simple moving average of $18.09. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.83 and a quick ratio of 1.83.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Monday, November 3rd. The company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.21. Pediatrix Medical Group had a net margin of 8.44% and a return on equity of 20.45%. The company had revenue of $492.88 million for the quarter, compared to analysts’ expectations of $476.45 million. During the same quarter in the previous year, the company earned $0.44 EPS. Pediatrix Medical Group’s revenue for the quarter was down 3.6% on a year-over-year basis. Equities analysts forecast that Pediatrix Medical Group will post 1.38 earnings per share for the current fiscal year.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.